GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » EV-to-EBITDA

Braxia Scientific (XCNQ:BRAX) EV-to-EBITDA : -0.21 (As of May. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Braxia Scientific's enterprise value is C$1.93 Mil. Braxia Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was C$-9.36 Mil. Therefore, Braxia Scientific's EV-to-EBITDA for today is -0.21.

The historical rank and industry rank for Braxia Scientific's EV-to-EBITDA or its related term are showing as below:

XCNQ:BRAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.17   Med: -0.4   Max: -0.01
Current: -0.21

During the past 3 years, the highest EV-to-EBITDA of Braxia Scientific was -0.01. The lowest was -6.17. And the median was -0.40.

XCNQ:BRAX's EV-to-EBITDA is ranked worse than
100% of 450 companies
in the Biotechnology industry
Industry Median: 9.57 vs XCNQ:BRAX: -0.21

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-27), Braxia Scientific's stock price is C$0.005. Braxia Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.047. Therefore, Braxia Scientific's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Braxia Scientific EV-to-EBITDA Historical Data

The historical data trend for Braxia Scientific's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific EV-to-EBITDA Chart

Braxia Scientific Annual Data
Trend Mar21 Mar22 Mar23
EV-to-EBITDA
-1.65 -0.28 -0.42

Braxia Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.42 -0.37 -0.36 -0.34

Competitive Comparison of Braxia Scientific's EV-to-EBITDA

For the Biotechnology subindustry, Braxia Scientific's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Braxia Scientific's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braxia Scientific's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Braxia Scientific's EV-to-EBITDA falls into.



Braxia Scientific EV-to-EBITDA Calculation

Braxia Scientific's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1.925/-9.363
=-0.21

Braxia Scientific's current Enterprise Value is C$1.93 Mil.
Braxia Scientific's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-9.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Braxia Scientific  (XCNQ:BRAX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Braxia Scientific's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.005/-0.047
=At Loss

Braxia Scientific's share price for today is C$0.005.
Braxia Scientific's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.047.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Braxia Scientific EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Braxia Scientific (XCNQ:BRAX) Business Description

Traded in Other Exchanges
Address
700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6
Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines